WHY NEGATIVE RESULTS IN CLINICAL TRIALS MATTER
International Clinical Trials Day 2026, a year in review: Trial of The Year 2025
With
Professor Brett J. Manley, Consultant Neonatologist
Mercy Hospital For Women, Melbourne &
Professor of Neonatal Medicine,
Department of Obstetrics, Gynaecology and Newborn Health,
University of Melbourne, Australia
Kate Francis, Biostatistician (Snr Research Officer)
Murdoch Children’s Research Institute, Melbourne &
Honorary Research Fellow,
Department of Paediatrics,
University of Melbourne &
Affiliate Biostatistician, The Royal Children’s Hospital, Melbourne, Australia
Professor Christopher Reid, Chair
Australian Clinical Trials Alliance (ACTA) &
School of Public Health and Preventive Medicine, Monash University &
School of Population Health at Curtin University,
Western Australia
A BENCH SIDE STORY SYNDICATION
Filmed in Melbourne & Perth | May 2026
Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.
The aim of the PLUSS trial was to find out if installation of budesonide (a steroid) with surfactant to the lungs of extremely preterm babies helps to prevent lung disease, or Bronchopulmonary dysplasia (BPD).
BPD is a chronic inflammatory lung disease characterised by disordered alveolar and vascular development, most commonly affecting extremely preterm infants exposed to mechanical ventilation and oxygen therapy for respiratory distress syndrome (RDS). BPD is associated with mortality, and adverse long-term pulmonary and neurodevelopmental outcomes. Despite advances in neonatal care including antenatal corticosteroids, exogenous surfactant, and the increasing use of non-invasive respiratory support, the incidence of BPD has increased in the state of Victoria in 2005 compared with earlier eras.
Extremely preterm infants participating in the trial were monitored closely after birth and an assessment completed at 36 weeks to check for BPD. Participating infants were also followed up when they are two years old.
The trial was led by a team of researchers at the Royal Women’s Hospital, Melbourne and the Liggins Institute in Auckland, New Zealand and had 29 participating centres around the world.
In 2025 the PLUSS Trial received the Australian Clinical Trials Alliance (ACTA) Trial of the Year 2025 Award as well as the ACTA STInG Excellence in Trial Statistics Award2025.
Source: Adapted from plusstrial.org website
As seen on Bench Side Story
You Might also like
-
Australian Healthcare and Hospitals Association Equipment Hospitals and Clinics New Content Paediatric
Health equity
For 30 years the Humpty Dumpty Foundation has worked to help bridge the gap that often exists between available resources and actual needs through the donation of paediatric medical equipment. Humpty, like many other charitable initiatives, began with a humble goal. Its Founder and Executive Chairman, Paul Francis OAM, together with Patron Ray Martin AM, set out to raise some money to paint the walls of the Children’s Ward at Royal North Shore Hospital.
To date more than 440 hospitals and health services have shared in over $85 million of essential and lifesaving medical equipment for sick and injured paediatric patients.
-
Environment / Sustainability Leadership New Content Orthopaedic Surgeon People in healthcare Research
Driven by purpose, defined by generosity and guided by a vision for better health
Adrian Cosenza is an experienced Chief Executive Officer and seasoned director, having served in an executive capacity in three industries including medical education, technology, and banking and finance and in a director capacity on over 15 boards across five industry sectors in four country jurisdictions.
-
Australia’s Nursing Crisis Snapshot
“Nursing, already under pressure, is reaching breaking point due to the pressures of COVID-19 and a disjointed healthcare system, including the acute, primary and aged care sectors”, says Kylie Ward, Australian College of Nursing CEO adding, “We must act now to protect our nurses and healthcare; the time has come for a national reckoning on nursing in Australia.”
Australian nurses cannot continue to work under the extreme pressure they are currently operating under – the impacts are mounting.
The almost 400,000 Australian nurses are a constant presence in every one of our major life milestones, national emergencies and global crises. The nurse of today holds a science degree, possesses highly technical training, valuable medical opinions, front-row expertise, is an effective trainer, and is skilled in population and systemic thinking. But the pandemic is inflicting a major emotional and physical toll on nurses.
In this “Perspectives” special, Australian Health Journal spoke with 4 nurses on the challenges they or nurses in their circle have experienced, the key issues as well some of the opportunities. These nurses come from national leadership & policy, large scale workforce management, a final year student completing over a year on placement across 6 Melbourne Hospitals and a NSW based ICU nurse stranded in Mexico, unable to return to a critical role in nursing to an already strained team due to incoming quotas.
While the issues are challenging, there are strategies that can be put into place to ease the pressure, to support nurses, and nursing care in Australia. These are discussed by the the 4 nurses.
– Adjunct Professor Kylie Ward FACN CEO, Australian College of Nursing
– Adjunct Professor Alanna Geary FACN ACN Chair of Workforce Sustainability Policy Chapter & Chief Nursing & Midwifery Officer, Metro North Health
– Natalie Reyes, NSW based ICU Nurse Currently stranded in Mexico
– Hayley Pollock, Final Year Bachelor of Nursing Student & ACN Emerging Nurse Leader
Post Views:
3,385